In this edition, physicians should question patients with restless leg syndrome about cannabis use ; digital therapeutic improves symptoms of insomnia, anxiety and depression; more efficient sleep may benefit patients with fibromyalgia and insomnia and more. Read the full coverage here: Physicians should question patients with restless leg syndrome about cannabis use Digital therapeutic improves symptoms of insomnia, anxiety, depression for 6 months More efficient sleep may benefit patients with fibromyalgia, insomnia FDA accepts new drug application, grants priority review for ALS treatment Quanterix announces validation of biomarker detection test to aid in diagnosis of AD References: Kachechian T, et al. Prevalence of cannabis use in patients with restless leg syndrome for symptomatic relief. Presented at: SLEEP; June 5-8, 2022; Charlotte, N.C. Nair N, et al. Effect of sleep on the relationship between pain-related disability and neural correlates of pain processing in adults with fibromyalgia and insomnia. Presented at: SLEEP; June 5-8, 2022; Charlotte, N.C. Press Release Press Release Press Release

Ver todos los episodios